NCT01536613已完成不适用
NovoMix® 30 FlexPen, Post Marketing Surveillance Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,346
- 主要终点
- Change in body weight
研究概览
简要总结
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with diabetes who did not have indications that are contraindicated in the product insert
排除标准
- 未提供
研究组 & 干预措施
BIAsp 30 users
干预措施: biphasic insulin aspart 30 (Drug)
结局指标
主要结局
Change in body weight
次要结局
- Change in HbA1c (glycosylated haemoglobin)
- Occurrence of adverse events (non-serious and serious)
- Change in fasting plasma glucose (FPG)
研究者
相似试验
已完成
不适用
NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaDiabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2NCT01492153Novo Nordisk A/S1,981
已完成
不适用
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanCongenital Bleeding DisorderHaemophilia ANCT02207218Novo Nordisk A/S40
已完成
不适用
Observational Study of NovoNorm® in Subjects With DiabetesDiabetesDiabetes Mellitus, Type 2NCT01498913Novo Nordisk A/S5,841
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)DiabetesDiabetes Mellitus, Type 2NCT02321878Novo Nordisk A/S1,092
已完成
不适用
Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical PracticeDelivery SystemsDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT01454024Novo Nordisk A/S1,031